目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 21)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 25)
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET RANKING ANALYSIS
2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 33)

4 PREMIUM INSIGHTS (Page No. - 37)
4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
4.2 ASIA PACIFIC: MARKET, BY END USER AND COUNTRY (2021)
4.3 GEOGRAPHICAL SNAPSHOT OF MARKET
4.4 MARKET, BY REGION
4.5 MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW (Page No. - 41)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing research activities using humanized models
5.2.1.2 Rising demand for personalized medicine
5.2.1.3 Continuous support and initiatives from government and private sectors for cancer research
5.2.1.4 Growing R&D activities in pharmaceutical and biotechnology sectors
5.2.2 RESTRAINTS
5.2.2.1 High cost of custom humanized models
5.2.2.2 Laws and regulations for ethical use of animal models in research
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for humanized PDX models
5.2.3.2 Emergence of CRISPR as a powerful tool in biomedical research
5.2.3.3 Rising demand for humanized rat models
5.2.4 CHALLENGES
5.2.4.1 Alternatives for animal testing
5.2.4.2 Limitations of humanized mouse models
5.3 REGULATORY ANALYSIS
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA PACIFIC
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.4 LATIN AMERICA
5.3.5 MIDDLE EAST & AFRICA
5.4 PRICING ANALYSIS
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS OF MARKET
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 PATENT ANALYSIS

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE (Page No. - 58)
6.1 INTRODUCTION
6.2 HUMANIZED MOUSE MODELS
6.2.1 GENETIC HUMANIZED MOUSE MODELS
6.2.1.1 Genetic humanized mouse models segment to account for larger market share
6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
6.2.2.1 CD34 humanized mouse models
6.2.2.1.1 Increasing demand for stem cell therapy to drive market growth
6.2.2.2 PBMC humanized mouse models
6.2.2.2.1 Growing prevalence of infectious diseases to drive demand
6.2.2.3 BLT humanized mouse models
6.2.2.3.1 Increasing HIV cases to drive demand
6.3 HUMANIZED RAT MODELS
6.3.1 LACK OF GERMLINE-COMPETENT RAT EMBRYONIC STEM CELL LINES AFFECTED ADOPTION OVER LAST TWO DECADES

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION (Page No. - 69)
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 INCREASING APPLICATIONS OF MOUSE MODELS IN CANCER STUDIES TO DRIVE GROWTH
7.3 IMMUNOLOGY AND INFECTIOUS DISEASES
7.3.1 DEVELOPMENT OF ADVANCED MODELS FOR HUMAN IMMUNOLOGY STUDIES TO BOOST GROWTH
7.4 NEUROSCIENCE
7.4.1 INCREASING FOCUS ON HUMANIZED MOUSE MODEL DEVELOPMENT FOR CNS DISORDERS TO PROPEL GROWTH
7.5 TOXICOLOGY
7.5.1 RISING NUMBER OF CLINICAL STUDIES TO DRIVE DEMAND
7.6 HEMATOPOIESIS
7.6.1 GROWING DEMAND FOR STEM CELL THERAPY TO PROPEL GROWTH
7.7 OTHER APPLICATIONS

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER (Page No. - 79)
8.1 INTRODUCTION
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING R&D ON DRUG DEVELOPMENT TO DRIVE GROWTH
8.3 CONTRACT RESEARCH ORGANIZATIONS
8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE GROWTH
8.4 ACADEMIC AND RESEARCH INSTITUTIONS
8.4.1 INCREASING LIFE SCIENCE R&D EXPENDITURE TO DRIVE GROWTH

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION (Page No. - 86)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 US to dominate North American market
9.2.2 CANADA
9.2.2.1 Government initiatives to drive market growth
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Germany to account for largest share in European market
9.3.2 UK
9.3.2.1 Increasing cancer research to drive growth
9.3.3 FRANCE
9.3.3.1 Increasing government funding for research and investments in genomics to drive growth
9.3.4 ITALY
9.3.4.1 Increasing pharmaceutical production in Italy to drive growth
9.3.5 SPAIN
9.3.5.1 Rising R&D expenditure to boost growth
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.1.1 China to dominate Asia Pacific market
9.4.2 JAPAN
9.4.2.1 Growing research collaborations to drive market growth in Japan
9.4.3 INDIA
9.4.3.1 Growing biotech industry in India to drive market growth
9.4.4 SOUTH KOREA
9.4.4.1 Growing efforts by government to drive market growth
9.4.5 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 INCREASING PHARMACEUTICAL R&D EXPENDITURE TO DRIVE MARKET GROWTH
9.6 MIDDLE EAST & AFRICA
9.6.1 UAE HAS EMERGED AS KEY MARKET IN MEA REGION

10 COMPETITIVE LANDSCAPE (Page No. - 134)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 MARKET SHARE ANALYSIS
10.4 COMPANY EVALUATION MATRIX
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
10.5 COMPANY EVALUATION MATRIX: START-UPS/SMES
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
10.6 FOOTPRINT ANALYSIS OF COMPANIES
10.6.1 PRODUCT FOOTPRINT OF COMPANIES
10.6.2 END-USER FOOTPRINT OF COMPANIES
10.6.3 REGIONAL FOOTPRINT OF COMPANIES
10.7 COMPETITIVE SCENARIO

11 COMPANY PROFILES (Page No. - 144)
11.1 KEY PLAYERS
11.1.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.4 MnM view
11.1.1.4.1 Key strengths/Right to win
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 THE JACKSON LABORATORY
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.4 MnM view
11.1.2.4.1 Key strengths/Right to win
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 TACONIC BIOSCIENCES, INC.
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.4 MnM view
11.1.3.4.1 Key strengths/Right to win
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 CROWN BIOSCIENCE
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 MnM view
11.1.4.3.1 Key strengths/Right to win
11.1.4.3.2 Strategic choices
11.1.4.3.3 Weaknesses and competitive threats
11.1.5 CHAMPIONS ONCOLOGY, INC.
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Key strengths/Right to win
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses and competitive threats
11.1.6 HERA BIOLABS
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.7 GENOWAY
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.8 ENVIGO
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.9 BEIJING VITALSTAR BIOTECHNOLOGY CO. LTD.
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 INGENIOUS TARGETING LABORATORY
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.11 AXENIS
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.12 TRANS GENIC
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.13 HARBOUR ANTIBODIES (A SUBSIDIARY OF HARBOUR BIOMED)
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.14 ONCODESIGN
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.15 PHARMATEST SERVICES
11.1.15.1 Business overview
11.1.15.2 Products offered
11.2 OTHER PLAYERS
11.2.1 OZGENE PTY LTD.
11.2.2 TRANSCURE BIOSERVICES
11.2.3 CYAGEN BIOSCIENCES
11.2.4 GVK BIO
11.2.5 BIOCYTOGEN

12 APPENDIX (Page No. - 171)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS

LIST OF TABLES (140 TABLES)
TABLE 1 NUMBER OF DRUGS IN DEVELOPMENT, BY DISEASE AREA (2020)
TABLE 2 PRICE OF HUMANIZED MOUSE MODELS (2022)
TABLE 3 SUPPLY CHAIN ECOSYSTEM
TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 6 HUMANIZED MOUSE MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 7 HUMANIZED MOUSE MODEL MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 8 GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 9 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 10 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 11 CD34 HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 12 PBMC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 13 BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 14 HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 15 MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 16 MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 17 MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 18 MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 19 MARKET FOR TOXICOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 20 MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 21 MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 22 MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 23 MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 24 MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 25 MODEL MARKET FOR ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 26 MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 27 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 28 NORTH AMERICA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 29 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 30 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 31 NORTH AMERICA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 32 NORTH AMERICA: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 33 US: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 34 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 35 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 36 US: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 37 US: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 38 CANADA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 39 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 40 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 41 CANADA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 42 CANADA: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 43 EUROPE: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 44 EUROPE: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 45 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 46 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 47 EUROPE: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 48 EUROPE: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 49 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 50 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 51 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 52 GERMANY: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 53 GERMANY: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 54 UK: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 55 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 56 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 57 UK: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 58 UK: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 59 FRANCE: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 60 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 61 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 62 FRANCE: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 63 FRANCE: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 64 ITALY: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 65 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 66 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 67 ITALY: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 68 ITALY: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 69 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 70 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 71 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 72 SPAIN: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 73 SPAIN: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 74 ROE: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 75 ROE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 76 ROE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 77 ROE: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 78 ROE: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 84 ASIA PACIFIC: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 85 CHINA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 86 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 87 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 88 CHINA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 89 CHINA: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 90 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 91 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 92 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 93 JAPAN: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 94 JAPAN: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 95 INDIA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 96 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 97 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 98 INDIA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 99 INDIA: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 100 SOUTH KOREA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 101 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 102 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 103 SOUTH KOREA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 104 SOUTH KOREA: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 105 ROAPAC: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 106 ROAPAC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 107 ROAPAC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 108 ROAPAC: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 109 ROAPAC: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 110 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 111 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 112 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 113 LATIN AMERICA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 114 LATIN AMERICA: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 116 MIDDLE EAST & AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 119 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 120 MARKET: DEGREE OF COMPETITION
TABLE 121 PRODUCT FOOTPRINT OF COMPANIES: MARKET (2021)
TABLE 122 END-USER FOOTPRINT OF COMPANIES: MARKET (2021)
TABLE 123 REGIONAL FOOTPRINT OF COMPANIES: MARKET (2021)
TABLE 124 PRODUCT LAUNCHES
TABLE 125 DEALS
TABLE 126 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
TABLE 127 THE JACKSON LABORATORY: BUSINESS OVERVIEW
TABLE 128 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW
TABLE 129 CROWN BIOSCIENCE: BUSINESS OVERVIEW
TABLE 130 CHAMPIONS ONCOLOGY: BUSINESS OVERVIEW
TABLE 131 HERA BIOLABS: BUSINESS OVERVIEW
TABLE 132 GENOWAY: BUSINESS OVERVIEW
TABLE 133 ENVIGO: BUSINESS OVERVIEW
TABLE 134 VITALSTAR BIOTECHNOLOGY: BUSINESS OVERVIEW
TABLE 135 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW
TABLE 136 AXENIS: BUSINESS OVERVIEW
TABLE 137 TRANS GENIC: BUSINESS OVERVIEW
TABLE 138 HARBOUR ANTIBODIES: BUSINESS OVERVIEW
TABLE 139 ONCODESIGN: BUSINESS OVERVIEW
TABLE 140 PHARMATEST SERVICES: BUSINESS OVERVIEW

LIST OF FIGURES (27 FIGURES)
FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 3 CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS,RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: FINAL CAGR PROJECTIONS
FIGURE 5 MARKET: SEGMENTAL ASSESSMENT
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 8 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 10 REGIONAL SNAPSHOT OF MARKET
FIGURE 11 GROWING RESEARCH ACTIVITIES USING HUMANIZED MODELS TO DRIVE MARKET GROWTH
FIGURE 12 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED ASIA PACIFIC MARKET IN 2021
FIGURE 13 INDIA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027
FIGURE 14 NORTH AMERICA TO DOMINATE MARKET IN 2027
FIGURE 15 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
FIGURE 16 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 CREATION OF HUMANIZED MODELS—MAXIMUM VALUE IS ADDED DURING IMPLANTATION OF GRAFT/TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
FIGURE 18 ECOSYSTEM ANALYSIS OF MARKET
FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT
FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT
FIGURE 21 KEY DEVELOPMENTS IN MARKET, 2019-2022
FIGURE 22 MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 23 MARKET: COMPANY EVALUATION MATRIX, 2021
FIGURE 24 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
FIGURE 25 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
FIGURE 26 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2021)
FIGURE 27 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2022)